CYP19A1 and breast cancer: In this regard, the main treatments for hormone-dependent BC (ER+/PR+) combined with adjuvant chemotherapy are based on hormonal therapy, which is based on the use of oestrogen antagonists, such as tamoxifen or fulvestrant and aromatase inhibitors like anastrozole, letrozole, and exemestane [22].